Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel
NASDAQ:CING

Cingulate Q2 2025 Earnings Report

Cingulate logo
$5.25 +0.16 (+3.16%)
As of 01:13 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Cingulate EPS Results

Actual EPS
-$1.09
Consensus EPS
-$0.82
Beat/Miss
Missed by -$0.27
One Year Ago EPS
N/A

Cingulate Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cingulate Announcement Details

Quarter
Q2 2025
Date
8/19/2025
Time
Before Market Opens
Conference Call Date
Tuesday, August 19, 2025
Conference Call Time
7:00AM ET

Conference Call Resources

Powered by Quartr

Earnings Documents

Cingulate's Q2 2025 Press ReleasePress Release
(8-K)
Cingulate's Q2 2025 Quarterly reportQuarterly report
(10-Q)

Cingulate Earnings Headlines

Psychedelic drug calms hyperactive brain cells linked to chronic pain
August 16 at 7:12 PM  |  msn.comhttps://www.msn.com/en-us/health/general/psychedelic-drug-calms-hyperactive-brain-cells-linked-to-chronic-pain/ar-AA2aeGPA
Cingulate (NASDAQ:CING) Raised to Sell at Wall Street Zen
August 15 at 2:01 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30961595
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.tc pixel
August 17 at 1:00 AM  |  Investors Alley (Ad)
Cingulate Reports $5.9 Million Second-Quarter Loss, $28.4 Million Cash
August 13, 2026  |  quiverquant.comQ
Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness
August 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/13/3344510/0/en/cingulate-inc-reports-second-quarter-2026-financial-results-and-provides-update-on-ctx-1301-cmc-progress-towards-nda-resubmission-and-commercial-readiness.html
Cingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301’s Differentiated Pharmacokinetic Profile
August 11, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/cingulate-publishes-peer-reviewed-data-demonstrating-ctx-1301-s-differentiated-pharmacokinetic-profile-1036440773
See More Cingulate Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cingulate? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cingulate and other key companies, straight to your email.

About Cingulate

Cingulate (NASDAQ:CING), a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

View Cingulate Profile
Earnings Tools